# MCP-1 en cardiovasculaire mortaliteit: populatie-gebaseerde meta-analyse

*geplaatst 2021-05-01 · Algemeen · JAMA cardiology · doi 10.1001/jamacardio.2020.5392 · https://hartvaat.nl/2021/05/01/mcp-1-en-cardiovasculaire-mortaliteit-populatie-gebaseerde-meta-analyse/*

Meta-analyse van populatiestudies naar de associatie van monocyt-chemoattractant proteïne-1 met cardiovasculaire mortaliteit.

## English: Association of Circulating Monocyte Chemoattractant Protein-1 Levels With Cardiovascular Mortality: A Meta-analysis of Population-Based Studies.

This meta-analysis confirmed that circulating MCP-1 (monocyte chemoattractant protein-1) is independently associated with cardiovascular mortality in population-based studies, supporting its role as an inflammatory risk biomarker.

## Abstract (original, from the publication)

IMPORTANCE: Human genetics and studies in experimental models support a key role of monocyte-chemoattractant protein-1 (MCP-1) in atherosclerosis. Yet, the associations of circulating MCP-1 levels with risk of coronary heart disease and cardiovascular death in the general population remain largely unexplored. OBJECTIVE: To explore whether circulating levels of MCP-1 are associated with risk of incident coronary heart disease, myocardial infarction, and cardiovascular mortality in the general population. DATA SOURCES AND SELECTION: Population-based cohort studies, identified through a systematic review, that have examined associations of circulating MCP-1 levels with cardiovascular end points. DATA EXTRACTION AND SYNTHESIS: Using a prespecified harmonized analysis plan, study-specific summary data were obtained from Cox regression models after excluding individuals with overt cardiovascular disease at baseline. Derived hazard ratios (HRs) were synthesized using random-effects meta-analyses. MAIN OUTCOMES AND MEASURES: Incident coronary heart disease (myocardial infarction, coronary revascularization, and unstable angina), nonfatal myocardial infarction, and cardiovascular death (from cardiac or cerebrovascular causes). RESULTS: The meta-analysis included 7 cohort studies involving 21 401 individuals (mean [SD] age, 53.7 [10.2] years; 10 012 men [46.8%]). Mean (SD) follow-up was 15.3 (4.5) years (326 392 person-years at risk). In models adjusting for age, sex, and race/ethnicity, higher MCP-1 levels at baseline were associated with increased risk of coronary heart disease (HR per 1-SD increment in MCP-1 levels: 1.06 [95% CI, 1.01-1.11]; P = .01), nonfatal myocardial infarction (HR, 1.07 [95% CI, 1.01-1.13]; P = .02), and cardiovascular death (HR, 1.12 [95% CI, 1.05-1.20]; P < .001). In analyses comparing MCP-1 quartiles, these associations followed dose-response patterns. After additionally adjusting for vascular risk factors, the risk estimates were attenuated, but the associations of MCP-1 levels with cardiovascular death remained statistically significant, as did the association of MCP-1 levels in the upper quartile with coronary heart disease. There was no significant heterogeneity; the results did not change in sensitivity analyses excluding events occurring in the first 5 years after MCP-1 measurement, and the risk estimates were stable after additional adjustments for circulating levels of interleukin-6 and high-sensitivity C-reactive protein. CONCLUSIONS AND RELEVANCE: Higher circulating MCP-1 levels are associated with higher long-term cardiovascular mortality in community-dwelling individuals free of overt cardiovascular disease. These findings provide further support for a key role of MCP-1-signaling in cardiovascular disease.

Auteurs: Marios K Georgakis, James A de Lemos, Colby Ayers, Biqi Wang, Harry Björkbacka, Tiberiu A Pana, Barbara Thorand, Caroline Sun, Lana Fani, Rainer Malik, Josée Dupuis, Gunnar Engström, Marju Orho-Melander, Olle Melander, S Matthijs Boekholdt, Astrid Zierer, Mohamed A Elhadad, Wolfgang Koenig, Christian Herder, Ron C Hoogeveen, Maryam Kavousi, Christie M Ballantyne, Annette Peters, Phyo K Myint, Jan Nilsson, Emelia J Benjamin, Martin Dichgans

---
Bron: JAMA cardiology, https://doi.org/10.1001/jamacardio.2020.5392. Bijgewerkt 2026-07-03T13:28:18Z. Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.